Novo Nordisk stock news
On June 25, 2026, Berenberg raised its price target for Novo Nordisk (NVO) while maintaining a "Buy" rating, citing increased confidence in the company's weight--loss market leadership following the recent UK approval of the oral Wegovy pill. This bullish outlook was supported by a concurrent UBS analysis projecting the global GLP--1 market for obesity and diabetes could reach up to $135 billion by 2030. These analyst actions reflect a positive shift in market sentiment as the company expands its oral medication portfolio to capture new patient segments.